

# Talitha L Feenstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5166214/publications.pdf>

Version: 2024-02-01

100  
papers

2,827  
citations

186265

28  
h-index

197818

49  
g-index

103  
all docs

103  
docs citations

103  
times ranked

3586  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries. <i>Pharmacoeconomics</i> , 2004, 22, 857-876.	3.3	219
2	Lifetime Medical Costs of Obesity: Prevention No Cure for Increasing Health Expenditure. <i>PLoS Medicine</i> , 2008, 5, e29.	8.4	200
3	The Impact of Aging and Smoking on the Future Burden of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 590-596.	5.6	190
4	Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. <i>European Respiratory Journal</i> , 2011, 37, 508-515.	6.7	152
5	Cost-Effectiveness of Face-to-Face Smoking Cessation Interventions: A Dynamic Modeling Study. <i>Value in Health</i> , 2005, 8, 178-190.	0.3	126
6	Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. <i>Thorax</i> , 2010, 65, 711-718.	5.6	111
7	A dynamic population model of disease progression in COPD. <i>European Respiratory Journal</i> , 2005, 26, 223-233.	6.7	102
8	Association between lung function and exacerbation frequency in patients with COPD. <i>International Journal of COPD</i> , 2010, 5, 435.	2.3	79
9	The Burden of Asthma and Chronic Obstructive Pulmonary Disease. <i>Pharmacoeconomics</i> , 2001, 19, 1-6.	3.3	69
10	Unrelated Medical Costs in Life-Years Gained. <i>Pharmacoeconomics</i> , 2008, 26, 815-830.	3.3	68
11	Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. <i>Cost Effectiveness and Resource Allocation</i> , 2008, 6, 1.	1.5	66
12	Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice. <i>Respiratory Medicine</i> , 2006, 100, 83-86.	2.9	63
13	Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a "perfect" cost-utility ratio. <i>Health Economics (United Kingdom)</i> , 2007, 16, 421-433.	1.7	63
14	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. <i>Value in Health</i> , 2018, 21, 724-731.	0.3	63
15	Cost-Effectiveness of Lifestyle Modification in Diabetic Patients. <i>Diabetes Care</i> , 2009, 32, 1453-1458.	8.6	52
16	Projecting the COPD population and costs in England and Scotland: 2011 to 2030. <i>Scientific Reports</i> , 2016, 6, 31893.	3.3	48
17	Economic evaluation and the postponement of health care costs. <i>Health Economics (United Kingdom)</i> , 2011, 20, 432-445.	1.7	44
18	Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus. <i>Pharmacoeconomics</i> , 2006, 24, 425-441.	3.3	42

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.3	41
20	Increasing tobacco taxes: A cheap tool to increase public health. <i>Health Policy</i> , 2007, 82, 142-152.	3.0	38
21	Decision makers's views on health care objectives and budget constraints: results from a pilot study. <i>Health Policy</i> , 2004, 70, 33-48.	3.0	34
22	Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial. <i>BMC Public Health</i> , 2014, 14, 1099.	2.9	34
23	The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 129-133.	2.1	33
24	Future costs in economic evaluation. <i>Journal of Health Economics</i> , 2008, 27, 1645-1649.	2.7	32
25	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , 2020, 23, 1163-1170.	0.3	32
26	Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. <i>Health Economics (United Kingdom)</i> , 2005, 14, 655-667.	1.7	31
27	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2011, 14, 1039-1047.	0.3	30
28	Simulation models in population breast cancer screening: A systematic review. <i>Breast</i> , 2015, 24, 354-363.	2.2	30
29	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017, Volume 12, 3183-3194.	2.3	30
30	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312.	3.3	28
31	Environmental policy instruments in an international duopoly with feedback investment strategies. <i>Journal of Economic Dynamics and Control</i> , 2001, 25, 1665-1687.	1.6	27
32	Prediction models for development of retinopathy in people with type 2 diabetes: systematic review and external validation in a Dutch primary care setting. <i>Diabetologia</i> , 2020, 63, 1110-1119.	6.3	27
33	Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study. <i>BMJ</i> , The, 2021, 374, n2134.	6.0	24
34	Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students. <i>Health Education Research</i> , 2007, 23, 310-318.	1.9	23
35	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403.	0.3	23
36	Tobacco Control Policies Specified According to Socioeconomic Status: Health Disparities and Cost-Effectiveness. <i>Nicotine and Tobacco Research</i> , 2014, 16, 725-732.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Decision models of prediabetes populations: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1558-1569.	4.4	21
38	Investment in antiviral drugs: a real options approach. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1240-1254.	1.7	20
39	Long-term incidence and risk factors of cardiovascular events in Asian populations: systematic review and meta-analysis of population-based cohort studies. <i>Current Medical Research and Opinion</i> , 2019, 35, 291-299.	1.9	20
40	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322.	3.3	19
41	Diabetes-Associated Factors as Predictors of Nursing Home Admission and Costs in the Elderly Across Europe. <i>Journal of the American Medical Directors Association</i> , 2017, 18, 74-82.	2.5	19
42	Reduction of smoking in Dutch adolescents over the past decade and its health gains: a repeated cross-sectional study. <i>European Journal of Public Health</i> , 2010, 20, 146-150.	0.3	17
43	Estimating disease prevalence from drug utilization data using the Random Forest algorithm. <i>European Journal of Public Health</i> , 2019, 29, 615-621.	0.3	17
44	If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. <i>Addiction</i> , 2010, 105, 1088-1097.	3.3	16
45	The cost-utility of stepped-care algorithms according to depression guideline recommendations – Results of a state-transition model analysis. <i>Journal of Affective Disorders</i> , 2019, 242, 244-254.	4.1	16
46	Continuous-Time Semi-Markov Models in Health Economic Decision Making. <i>Medical Decision Making</i> , 2016, 36, 59-71.	2.4	15
47	Improving Model Validation in Health Technology Assessment: Comments on Guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force. <i>Value in Health</i> , 2013, 16, 1106-1107.	0.3	14
48	Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. <i>European Journal of Health Economics</i> , 2013, 14, 947-957.	2.8	14
49	Cost-effectiveness of implant-supported mandibular removable partial dentures. <i>Clinical Oral Implants Research</i> , 2017, 28, 594-601.	4.5	14
50	Early health technology assessment of magnetic resonance-guided high intensity focused ultrasound ablation for the treatment of early-stage breast cancer. <i>Journal of Therapeutic Ultrasound</i> , 2017, 5, 23.	2.2	14
51	A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening. <i>Maturitas</i> , 2018, 109, 81-88.	2.4	14
52	Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. <i>PLoS ONE</i> , 2019, 14, e0212328.	2.5	14
53	Resource use and costs of type 2 diabetes patients receiving managed or protocolized primary care: a controlled clinical trial. <i>BMC Health Services Research</i> , 2014, 14, 280.	2.2	13
54	Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study. <i>Oncotarget</i> , 2018, 9, 19836-19846.	1.8	13

#	ARTICLE	IF	CITATIONS
55	Cost effectiveness of guideline advice for children with asthma: A literature review. <i>Pediatric Pulmonology</i> , 2002, 34, 442-454.	2.0	12
56	Costs and health effects of adding functional foods containing phytosterols/-stanols to statin therapy in the prevention of cardiovascular disease. <i>European Journal of Pharmacology</i> , 2011, 668, S91-S100.	3.5	12
57	Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer. <i>Value in Health</i> , 2015, 18, 84-90.	0.3	12
58	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.3	11
59	A social cost-benefit analysis of two One Health interventions to prevent toxoplasmosis. <i>PLoS ONE</i> , 2019, 14, e0216615.	2.5	11
60	Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 269-279.	1.4	11
61	Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer. <i>Pharmacoeconomics</i> , 2016, 34, 833-845.	3.3	10
62	A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. <i>Value in Health</i> , 2017, 20, 1041-1047.	0.3	10
63	Prognostic models for predicting the risk of foot ulcer or amputation in people with type 2 diabetes: a systematic review and external validation study. <i>Diabetologia</i> , 2021, 64, 1550-1562.	6.3	10
64	A personalised screening strategy for diabetic retinopathy: a cost-effectiveness perspective. <i>Diabetologia</i> , 2020, 63, 2452-2461.	6.3	9
65	Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention. <i>Cost Effectiveness and Resource Allocation</i> , 2011, 9, 14.	1.5	8
66	Cost effectiveness and budgetary impact of the Boston University approach to Psychiatric Rehabilitation for societal participation in people with severe mental illness: a randomised controlled trial protocol. <i>BMC Psychiatry</i> , 2015, 15, 217.	2.6	8
67	Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? " A cost-effectiveness analysis. <i>Breast</i> , 2019, 45, 82-88.	2.2	8
68	Smoking-attributable burden of lung cancer in Mongolia a data synthesis study on differences between men and women. <i>PLoS ONE</i> , 2020, 15, e0229090.	2.5	8
69	Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems. <i>European Journal of Health Economics</i> , 2020, 21, 689-702.	2.8	8
70	Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1084-1091.	4.4	8
71	Value of Information Analysis from a Societal Perspective: A Case Study in Prevention of Major Depression. <i>Value in Health</i> , 2013, 16, 490-497.	0.3	7
72	Effectiveness of the Boston University Approach to Psychiatric Rehabilitation in Improving Social Participation in People With Severe Mental Illnesses: A Randomized Controlled Trial. <i>Frontiers in Psychiatry</i> , 2020, 11, 571640.	2.6	7

#	ARTICLE	IF	CITATIONS
73	Real-World Treatment Costs and Care Utilization in Patients with Major Depressive Disorder With and Without Psychiatric Comorbidities in Specialist Mental Healthcare. <i>Pharmacoeconomics</i> , 2021, 39, 721-730.	3.3	7
74	COPD: can prevention be improved? Proposal for an integrated intervention strategy. <i>Preventive Medicine</i> , 2004, 39, 337-343.	3.4	6
75	The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders. <i>PLoS ONE</i> , 2019, 14, e0225626.	2.5	6
76	Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. <i>Pharmacoeconomics</i> , 2018, 36, 105-113.	3.3	5
77	The clinical effectiveness of an algorithm-guided treatment program for depression in specialized mental healthcare: A comparison with efficacy trials. <i>Journal of Affective Disorders</i> , 2020, 275, 216-223.	4.1	5
78	Health-related quality of life for normal glycaemia, prediabetes and type 2 diabetes mellitus: Cross-sectional analysis of the ADDITION-PRO study. <i>Diabetic Medicine</i> , 2022, 39, e14825.	2.3	5
79	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge. <i>Medical Decision Making</i> , 2022, 42, 599-611.	2.4	5
80	Computer simulation models of pre-diabetes populations: a systematic review protocol. <i>BMJ Open</i> , 2017, 7, e014954.	1.9	4
81	Four Aspects Affecting Health Economic Decision Models and Their Validation. <i>Pharmacoeconomics</i> , 2022, 40, 241-248.	3.3	4
82	More than cost-effectiveness? Applying a second-stage filter to improve policy decision making. <i>Health Expectations</i> , 2021, 24, 1413-1423.	2.6	3
83	Informing policy makers on the efficiency of population level tobacco control interventions in Asia: A systematic review of model-based economic evaluations. <i>Journal of Global Health</i> , 2020, 10, 020437.	2.7	3
84	The costs of inappropriate referral pathways in inpatient care for three major noncommunicable diseases in Mongolia: a national registry-based analysis. <i>BMC Health Services Research</i> , 2021, 21, 1280.	2.2	3
85	Communicating Uncertainty in Economic Evaluations. <i>Medical Decision Making</i> , 2012, 32, 477-487.	2.4	2
86	Dealing With Missing Behavioral Endpoints in Health Promotion Research by Modeling Cognitive Parameters in Cost-Effectiveness Analyses of Behavioral Interventions: A Validation Study. <i>Health Economics (United Kingdom)</i> , 2016, 25, 24-39.	1.7	2
87	Costs of people with diabetes in relation to average glucose control: an empirical approach controlling for year of onset cohorts. <i>European Journal of Health Economics</i> , 2019, 20, 989-1000.	2.8	2
88	The transferability and validity of a population-level simulation model for the economic evaluation of interventions in diabetes: the MICADO model. <i>Acta Diabetologica</i> , 2022, 59, 949-957.	2.5	2
89	Personalizing the Use of a Intermittently Scanned Continuous Glucose Monitoring Device in Individuals With Type 1 Diabetes: A Cost-Effectiveness Perspective in the Netherlands (FLARE-NL 9). <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 135-142.	2.2	2
90	I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 55-70.	0.2	1

#	ARTICLE	IF	CITATIONS
91	LONG-TERM EFFECTS OF ALCOHOL POLICIES: AN ECONOMIC PERSPECTIVE. <i>Addiction</i> , 2010, 105, 395-397.	3.3	1
92	Potential reach of effective smoking prevention programmes in vocational schools: Determinants of school directors' intention to adopt these programmes. <i>Public Health</i> , 2012, 126, 338-342.	2.9	1
93	Costs of minor bleeds in atrial fibrillation patients using a non-vitamin K antagonist oral anticoagulant. <i>Current Medical Research and Opinion</i> , 2021, 37, 1461-1466.	1.9	1
94	Cost Effectiveness and Budget Impact of the Boston University Approach to Psychiatric Rehabilitation for Increasing the Social Participation of Individuals With Severe Mental Illnesses. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	1
95	Reply to the Comment by Van der Deen Et al.: "Possible Methodological Reason for the Finding That Neither Tax Increase nor Reimbursement Reduced Health Disparities". <i>Nicotine and Tobacco Research</i> , 2014, 16, 1031-1032.	2.6	0
96	Correspondence "Reply to THEBREAST-D-15-702. <i>Breast</i> , 2016, 27, 184-185.	2.2	0
97	Episode detection based on personalized intensity of care thresholds: a schizophrenia case study. <i>Social Science and Medicine</i> , 2021, 270, 113507.	3.8	0
98	Reducing the Burden of Disease Through Tobacco Taxes in Mongolia: A Health Impact Analysis Using a Dynamic Public Health Model. <i>Nicotine and Tobacco Research</i> , 2022, 24, 233-240.	2.6	0
99	External validation of exacerbation and mortality outcomes of health economic decision models for COPD. , 2016, , .		0
100	Prediction models for exacerbations in different COPD patient populations: Results of five large databases. , 2016, , .		0